Inhibitor of differentiation 4 (ID4): From development to cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1855, Issue 1, 2015, Pages 92-103

  Patel, Divya ^a   Morton, Derrick J ^a   Carey, Jason ^b   Havrda, Mathew C ^c   Chaudhary, Jaideep ^a  

^a CLARK ATLANTA UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

BHLH; Cancer; Development; Differentiation; Epigenetics; ID4

Indexed keywords

ANDROGEN RECEPTOR; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CISPLATIN; DOXORUBICIN; ESTROGEN RECEPTOR; INHIBITOR OF DIFFERENTIATION 1; INHIBITOR OF DIFFERENTIATION 2; INHIBITOR OF DIFFERENTIATION 3; INHIBITOR OF DIFFERENTIATION 4; INHIBITOR OF DIFFERENTIATION PROTEIN; MICRORNA; PROTEIN P53; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; ID4 PROTEIN, HUMAN;

ADVANCED CANCER; BASAL CELL CARCINOMA; BRANCHING MORPHOGENESIS; BREAST CANCER; BREAST DEVELOPMENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL CYCLE ARREST; CELL SURVIVAL; CHROMOSOME TRANSLOCATION; DEVELOPMENT; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; KNOCKOUT MOUSE; MALIGNANT TRANSFORMATION; NEOPLASM; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OSTEOPOROSIS; OVARY CANCER; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; RECURRENCE FREE SURVIVAL; REVIEW; SPERMATOGENESIS; TRANSCRIPTION REGULATION; TUMOR VASCULARIZATION; ADULT; AMINO ACID SEQUENCE; ANIMAL; CELL DIFFERENTIATION; CHEMISTRY; CLASSIFICATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; MOLECULAR GENETICS; MOUSE; PATHOLOGY; PHYLOGENY; PHYSIOLOGY; SEQUENCE HOMOLOGY;

ANIMALIA; MUS;

ADULT; AMINO ACID SEQUENCE; ANIMALS; CELL DIFFERENTIATION; GROWTH AND DEVELOPMENT; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEINS; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; NEOPLASMS; PHYLOGENY; SEQUENCE HOMOLOGY;

EID: 84918790496     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.12.002     Document Type: Review

References (111)

1. Ruzinova M.B., Benezra R. Id proteins in development, cell cycle and cancer. Trends Cell Biol. 2003, 13:410-418.
2. Riechmann V., van Cruchten I., Sablitzky F. The expression pattern of Id4, a novel dominant negative helix-loop-helix protein, is distinct from Id1, Id2 and Id3. Nucleic Acids Res. 1994, 22:749-755.
3. Gabellini C., Del Bufalo D., Zupi G. Involvement of RB gene family in tumor angiogenesis. Oncogene 2006, 25:5326-5332.
4. Kumar D., Shadrach J.L., Wagers A.J., Lassar A.B. Id3 is a direct transcriptional target of Pax7 in quiescent satellite cells. Mol. Biol. Cell 2009, 20:3170-3177.
5. Lasorella A., Benezra R., Iavarone A. The ID proteins: master regulators of cancer stem cells and tumour aggressiveness. Nat. Rev. Cancer 2014, 14:77-91.
6. Ling F., Kang B., Sun X.-H. Chapter five - Id proteins: small molecules, mighty regulators. Current Topics in Developmental Biology 2014, Volume 110:189-216. Academic Press. T. Reshma (Ed.).
7. Coppe J.P., Smith A.P., Desprez P.Y. Id proteins in epithelial cells. Exp. Cell Res. 2003, 285:131-145.
8. Hasskarl J., Munger K. Id proteins-tumor markers or oncogenes?. Cancer Biol. Ther. 2002, 1:91-96.
9. Pagliuca A., Bartoli P.C., Saccone S., Della Valle G., Lania L. Molecular cloning of ID4, a novel dominant negative helix-loop-helix human gene on chromosome 6p21.3-p22. Genomics 1995, 27:200-203.
10. Kiewitz S.D., Cabrele C. Synthesis and conformational properties of protein fragments based on the Id family of DNA-binding and cell-differentiation inhibitors. Biopolymers 2005, 80:762-774.
11. Campuzano S. Emc, a negative HLH regulator with multiple functions in Drosophila development. Oncogene 2001, 20:8299-8307.
12. Mortlock D.P., Sateesh P., Innis J.W. Evolution of N-terminal sequences of the vertebrate HOXA13 protein. Mamm. Genome 2000, 11:151-158.
13. Sumiyama K., Washio-Watanabe K., Saitou N., Hayakawa T., Ueda S. Class III POU genes: generation of homopolymeric amino acid repeats under GC pressure in mammals. J. Mol. Evol. 1996, 43:170-178.
14. Amiel J., Trochet D., Clement-Ziza M., Munnich A., Lyonnet S. Polyalanine expansions in human. Hum. Mol. Genet. 2004, 13(2):R235-R243.
15. Pelassa I., Cora D., Cesano F., Monje F.J., Montarolo P.G., Fiumara F. Association of polyalanine and polyglutamine coiled coils mediates expansion disease-related protein aggregation and dysfunction. Hum. Mol. Genet. 2014, 23:3402-3420.
16. Dunker A.K., Lawson J.D., Brown C.J., Williams R.M., Romero P., Oh J.S., Oldfield C.J., Campen A.M., Ratliff C.M., Hipps K.W., Ausio J., Nissen M.S., Reeves R., Kang C., Kissinger C.R., Bailey R.W., Griswold M.D., Chiu W., Garner E.C., Obradovic Z. Intrinsically disordered protein. J. Mol. Graph. Model. 2001, 19:26-59.
17. Kini R.M., Evans H.J. A hypothetical structural role for proline residues in the flanking segments of protein-protein interaction sites. Biochem. Biophys. Res. Commun. 1995, 212:1115-1124.
18. Romero P., Obradovic Z., Kissinger C., Villafranca J.E., Dunker A.K. Identifying disordered regions in proteins from amino acid sequence. Neural Networks, 1997., International Conference on 1997, vol. 1:90-95. vol. 91.
19. Haynes C., Oldfield C.J., Ji F., Klitgord N., Cusick M.E., Radivojac P., Uversky V.N., Vidal M., Iakoucheva L.M. Intrinsic disorder is a common feature of hub proteins from four eukaryotic interactomes. PLoS Comput. Biol. 2006, 2:e100.
20. Jen Y., Manova K., Benezra R. Expression patterns of Id1, Id2, and Id3 are highly related but distinct from that of Id4 during mouse embryogenesis. Dev. Dyn. 1996, 207:235-252.
21. Rigolet M., Rich T., Gross-Morand M.S., Molina-Gomes D., Viegas-Pequignot E., Junien C. cDNA cloning, tissue distribution and chromosomal localization of the human ID4 gene. DNA Res. 1998, 5:309-313.
22. Dong J., Huang S., Caikovski M., Ji S., McGrath A., Custorio M.G., Creighton C.J., Maliakkal P., Bogoslovskaia E., Du Z., Zhang X., Lewis M.T., Sablitzky F., Brisken C., Li Y. ID4 regulates mammary gland development by suppressing p38MAPK activity. Development 2011, 138:5247-5256.
23. Sharma P., Knowell A.E., Chinaranagari S., Komaragiri S., Nagappan P., Patel D., Havrda M.C., Chaudhary J. Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTEN. Mol. Cancer 2013, 12:67.
24. Tokuzawa Y., Yagi K., Yamashita Y., Nakachi Y., Nikaido I., Bono H., Ninomiya Y., Kanesaki-Yatsuka Y., Akita M., Motegi H., Wakana S., Noda T., Sablitzky F., Arai S., Kurokawa R., Fukuda T., Katagiri T., Schonbach C., Suda T., Mizuno Y., Okazaki Y. Id4, a new candidate gene for senile osteoporosis, acts as a molecular switch promoting osteoblast differentiation. PLoS Genet. 2010, 6:e1001019.
25. Murad J.M., Place C.S., Ran C., Hekmatyar S.K., Watson N.P., Kauppinen R.A., Israel M.A. Inhibitor of DNA binding 4 (ID4) regulation of adipocyte differentiation and adipose tissue formation in mice. J. Biol. Chem. 2010, 285:24164-24173.
26. Yun K., Mantani A., Garel S., Rubenstein J., Israel M.A. Id4 regulates neural progenitor proliferation and differentiation in vivo. Development 2004, 131:5441-5448.
27. Chaudhary J., Johnson J., Kim G., Skinner M.K. Hormonal regulation and differential actions of the helix-loop-helix transcriptional inhibitors of differentiation (Id1, Id2, Id3, and Id4) in Sertoli cells. Endocrinology 2001, 142:1727-1736.
28. Huang J., Vogel G., Yu Z., Almazan G., Richard S. Type II arginine methyltransferase PRMT5 regulates gene expression of inhibitors of differentiation/DNA binding Id2 and Id4 during glial cell differentiation. J. Biol. Chem. 2011, 286:44424-44432.
29. Oatley M.J., Kaucher A.V., Racicot K.E., Oatley J.M. Inhibitor of DNA binding 4 is expressed selectively by single spermatogonia in the male germline and regulates the self-renewal of spermatogonial stem cells in mice. Biol. Reprod. 2011, 85:347-356.
30. Sablitzky F., Moore A., Bromley M., Deed R.W., Newton J.S., Norton J.D. Stage- and subcellular-specific expression of Id proteins in male germ and Sertoli cells implicates distinctive regulatory roles for Id proteins during meiosis, spermatogenesis, and Sertoli cell function. Cell Growth Differ. 1998, 9:1015-1024.
31. Marin-Husstege M., He Y., Li J., Kondo T., Sablitzky F., Casaccia-Bonnefil P. Multiple roles of Id4 in developmental myelination: predicted outcomes and unexpected findings. Glia 2006, 54:285-296.
32. Kondo T., Raff M. The Id4 HLH protein and the timing of oligodendrocyte differentiation. EMBO J. 2000, 19:1998-2007.
33. Blake J.A., Bult C.J., Eppig J.T., Kadin J.A., Richardson J.E., Mouse Genome Database G. The Mouse Genome Database: integration of and access to knowledge about the laboratory mouse. Nucleic Acids Res 2014, 42:D810-817.
34. Bedford L., Walker R., Kondo T., van Cruchten I., King E.R., Sablitzky F. Id4 is required for the correct timing of neural differentiation. Dev. Biol. 2005, 280:386-395.
35. Best S.A., Hutt K.J., Fu N.Y., Vaillant F., Liew S.H., Hartley L., Scott C.L., Lindeman G.J., Visvader J.E. Dual roles for Id4 in the regulation of estrogen signaling in the mammary gland and ovary. Development 2014, 141:3159-3164.
36. Sikder H.A., Devlin M.K., Dunlap S., Ryu B., Alani R.M. Id proteins in cell growth and tumorigenesis. Cancer Cell 2003, 3:525-530.
37. Wice B.M., Gordon J.I. Forced expression of Id-1 in the adult mouse small intestinal epithelium is associated with development of adenomas. J. Biol. Chem. 1998, 273:25310-25319.
38. Verschuur-Maes A.H., de Bruin P.C., van Diest P.J. Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer. Breast Cancer Res. Treat. 2012, 136:705-715.
39. Roldan G., Delgado L., Muse I.M. Tumoral expression of BRCA1, estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer. Cancer Biol. Ther. 2006, 5:505-510.
40. de Candia P., Akram M., Benezra R., Brogi E. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma. Hum. Pathol. 2006, 37:1032-1041.
41. Turner N.C., Reis-Filho J.S., Russell A.M., Springall R.J., Ryder K., Steele D., Savage K., Gillett C.E., Schmitt F.C., Ashworth A., Tutt A.N. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007, 26:2126-2132.
42. Park S.J., Kim R.J., Nam J.S. Inhibitor of DNA-binding 4 contributes to the maintenance and expansion of cancer stem cells in 4T1 mouse mammary cancer cell line. Lab. Anim. Res. 2011, 27:333-338.
43. Branham M.T., Marzese D.M., Laurito S.R., Gago F.E., Orozco J.I., Tello O.M., Vargas-Roig L.M., Roque M. Methylation profile of triple-negative breast carcinomas. Oncogenesis 2012, 1:e17.
44. Kim S., Kon M., DeLisi C. Pathway-based classification of cancer subtypes. Biol. Direct 2012, 7:21.
45. Schnitt S.J. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod. Pathol. 2010, 23:S60-S64.
46. Ren Y., Cheung H.W., von Maltzhan G., Agrawal A., Cowley G.S., Weir B.A., Boehm J.S., Tamayo P., Karst A.M., Liu J.F., Hirsch M.S., Mesirov J.P., Drapkin R., Root D.E., Lo J., Fogal V., Ruoslahti E., Hahn W.C., Bhatia S.N. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci. Transl. Med. 2012, 4:147ra112.
47. Zeng W., Rushing E.J., Hartmann D.P., Azumi N. Increased inhibitor of differentiation 4 (id4) expression in glioblastoma: a tissue microarray study. J. Cancer 2010, 1:1-5.
48. Wu Q., Hoffmann M.J., Hartmann F.H., Schulz W.A. Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer. Mol. Cancer 2005, 4:16.
49. Slovak M.L., Bedell V., Hsu Y.H., Estrine D.B., Nowak N.J., Delioukina M.L., Weiss L.M., Smith D.D., Forman S.J. Molecular karyotypes of Hodgkin and Reed-Sternberg cells at disease onset reveal distinct copy number alterations in chemosensitive versus refractory Hodgkin lymphoma. Clin. Cancer Res. 2011, 17:3443-3454.
50. Bellido M., Aventin A., Lasa A., Estivill C., Carnicer M.J., Pons C., Matias-Guiu X., Bordes R., Baiget M., Sierra J., Nomdedeu J.F. Id4 is deregulated by a t(6;14)(p22;q32) chromosomal translocation in a B-cell lineage acute lymphoblastic leukemia. Haematologica 2003, 88:994-1001.
51. Hu H.B., Hu Q. [ID4 methylation patterns in childhood T line and B line lymphocytic leukemia.], Zhongguo dang dai er ke za zhi =. Chin. J. Contemp. Pediatr. 2010, 12:940-942.
52. Carey J.P., Asirvatham A.J., Galm O., Ghogomu T.A., Chaudhary J. Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer. BMC Cancer 2009, 9:173.
53. Yu L., Liu C., Vandeusen J., Becknell B., Dai Z., Wu Y.Z., Raval A., Liu T.H., Ding W., Mao C., Liu S., Smith L.T., Lee S., Rassenti L., Marcucci G., Byrd J., Caligiuri M.A., Plass C. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat. Genet. 2005, 37:265-274.
54. Castro M., Grau L., Puerta P., Gimenez L., Venditti J., Quadrelli S., Sanchez-Carbayo M. Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J. Transl. Med. 2010, 8:86.
55. Uhm K.O., Lee E.S., Lee Y.M., Kim H.S., Park Y.N., Park S.H. Aberrant promoter CpG islands methylation of tumor suppressor genes in cholangiocarcinoma. Oncol. Res. 2008, 17:151-157.
56. Noetzel E., Veeck J., Niederacher D., Galm O., Horn F., Hartmann A., Knuchel R., Dahl E. Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer 2008, 8:154.
57. Umetani N., Takeuchi H., Fujimoto A., Shinozaki M., Bilchik A.J., Hoon D.S. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin. Cancer Res. 2004, 10:7475-7483.
58. Jiang D., Hong Q., Shen Y., Xu Y., Zhu H., Li Y., Xu C., Ouyang G., Duan S. The diagnostic value of DNA methylation in leukemia: a systematic review and meta-analysis. PLoS One 2014, 9:e96822.
59. Chen S.S., Claus R., Lucas D.M., Yu L., Qian J., Ruppert A.S., West D.A., Williams K.E., Johnson A.J., Sablitzky F., Plass C., Byrd J.C. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood 2011, 117:862-871.
60. Martini M., Cenci T., D'Alessandris G.Q., Cesarini V., Cocomazzi A., Ricci-Vitiani L., De Maria R., Pallini R., Larocca L.M. Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis. Cancer 2013, 119:1004-1012.
61. Ruchusatsawat K., Wongpiyabovorn J., Protjaroen P., Chaipipat M., Shuangshoti S., Thorner P.S., Mutirangura A. Parakeratosis in skin is associated with loss of inhibitor of differentiation 4 via promoter methylation. Hum. Pathol. 2011, 42:1878-1887.
62. Chan A.S., Tsui W.Y., Chen X., Chu K.M., Chan T.L., Li R., So S., Yuen S.T., Leung S.Y. Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma. Oncogene 2003, 22:6946-6953.
63. Vincent A., Omura N., Hong S.M., Jaffe A., Eshleman J., Goggins M. Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clin. Cancer Res. 2011, 17:4341-4354.
64. Gomez Del Pulgar T., Valdes-Mora F., Bandres E., Perez-Palacios R., Espina C., Cejas P., Garcia-Cabezas M.A., Nistal M., Casado E., Gonzalez-Baron M., Garcia-Foncillas J., Lacal J.C. Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism. Int. J. Oncol. 2008, 33:185-193.
65. Hagiwara K., Nagai H., Li Y., Ohashi H., Hotta T., Saito H. Frequent DNA methylation but not mutation of the ID4 gene in malignant lymphoma. J. Clin. Exp. Hematop. 2007, 47:15-18.
66. Smith E., De Young N.J., Pavey S.J., Hayward N.K., Nancarrow D.J., Whiteman D.C., Smithers B.M., Ruszkiewicz A.R., Clouston A.D., Gotley D.C., Devitt P.G., Jamieson G.G., Drew P.A. Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma. Mol. Cancer 2008, 7:75.
67. Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., Barrette T., Pandey A., Chinnaiyan A.M. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6.
68. Sharma P., Chinaranagari S., Patel D., Carey J., Chaudhary J. Epigenetic inactivation of inhibitor of differentiation 4 (Id4) correlates with prostate cancer. Cancer Med. 2012, 1.
69. Knowell A.E., Patel D., Morton D.J., Sharma P., Glymph S., Chaudhary J. Id4 dependent acetylation restores mutant-p53 transcriptional activity. Mol. Cancer 2013, 12:161.
70. Lin M.F., Meng T.C., Rao P.S., Chang C., Schonthal A.H., Lin F.F. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J. Biol. Chem. 1998, 273:5939-5947.
71. Vinarskaja A., Goering W., Ingenwerth M., Schulz W.A. ID4 is frequently downregulated and partially hypermethylated in prostate cancer. World J. Urol. 2012, 30:319-325.
72. Patel D., Knowell A.E., Korang-Yeboah M., Sharma P., Joshi J., Glymph S., Chinaranagari S., Nagappan P., Palaniappan R., Bowen N.J., Chaudhary J. Inhibitor of differentiation 4 (ID4) inactivation promotes de novo steroidogenesis and castration-resistant prostate cancer. Mol. Endocrinol. 2014, 28:1239-1253.
73. Wang X.R., Kang H.Y., Cen J., Li Y.H., Wang L.L., Yu L. [Methylation status of id4 gene promoter in patients with chronic myeloid leukemia], Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui. J. exp. hematol. Chin. Assoc. Pathophysiol. 2010, 18:1402-1404.
74. Wang H., Wang X.Q., Xu X.P., Lin G.W. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome. Leuk. Res. 2010, 34:598-604.
75. Uhm K.O., Lee E.S., Lee Y.M., Park J.S., Kim S.J., Kim B.S., Kim H.S., Park S.H. Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia. J. Korean Med. Sci. 2009, 24:493-497.
76. Kuzontkoski P.M., Mulligan-Kehoe M.J., Harris B.T., Israel M.A. Inhibitor of DNA binding-4 promotes angiogenesis and growth of glioblastoma multiforme by elevating matrix GLA levels. Oncogene 2010, 29:3793-3802.
77. Fontemaggi G., Dell'Orso S., Trisciuoglio D., Shay T., Melucci E., Fazi F., Terrenato I., Mottolese M., Muti P., Domany E., Del Bufalo D., Strano S., Blandino G. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat. Struct. Mol. Biol. 2009, 16:1086-1093.
78. Jeon H.M., Sohn Y.W., Oh S.Y., Kim S.H., Beck S., Kim S., Kim H. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res. 2011, 71:3410-3421.
79. Yuen H.F., Chua C.W., Chan Y.P., Wong Y.C., Wang X., Chan K.W. Id proteins expression in prostate cancer: high-level expression of Id-4 in primary prostate cancer is associated with development of metastases. Mod. Pathol. 2006, 19:931-941.
80. Rahme G.J., Israel M.A. Id4 suppresses MMP2-mediated invasion of glioblastoma-derived cells by direct inactivation of Twist1 function. Oncogene 2014, (Epub ahead of print). 10.1038/onc.2013.531.
81. Jeon H.M., Jin X., Lee J.S., Oh S.Y., Sohn Y.W., Park H.J., Joo K.M., Park W.Y., Nam D.H., DePinho R.A., Chin L., Kim H. Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling. Genes Dev. 2008, 22:2028-2033.
82. Pagliuca A., Cannada-Bartoli P., Lania L. A role for Sp and helix-loop-helix transcription factors in the regulation of the human Id4 gene promoter activity. J. Biol. Chem. 1998, 273:7668-7674.
83. Lu X.C., Chi X.H., Lou F.D., Zhu H.L., Fan H., Li S.X., Yu L. [Bioinformatics scan analysis for predicting drug targeted modulation on ID4 gene expression], Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui. J. exp. hematol. Chin. Assoc. Pathophysiol. 2007, 15:594-598.
84. Wen Y.H., Ho A., Patil S., Akram M., Catalano J., Eaton A., Norton L., Benezra R., Brogi E. Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation. Breast Cancer Res. Treat. 2012, 135:93-102.
85. Welcsh P.L., Lee M.K., Gonzalez-Hernandez R.M., Black D.J., Mahadevappa M., Swisher E.M., Warrington J.A., King M.C. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:7560-7565.
86. Thompson V.C., Day T.K., Bianco-Miotto T., Selth L.A., Han G., Thomas M., Buchanan G., Scher H.I., Nelson C.C., Greenberg N.M., Butler L.M., Tilley W.D. A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. Int. J. Cancer 2012, 131:662-672.
87. Samanta J., Kessler J.A. Interactions between ID and OLIG proteins mediate the inhibitory effects of BMP4 on oligodendroglial differentiation. Development 2004, 131:4131-4142.
88. Srikanth M., Kim J., Das S., Kessler J.A. BMP signaling induces astrocytic differentiation of clinically derived oligodendroglioma propagating cells. Mol. Cancer Res. 2014, 12:283-294.
89. Crippa E., Lusa L., De Cecco L., Marchesi E., Calin G.A., Radice P., Manoukian S., Peissel B., Daidone M.G., Gariboldi M., Pierotti M.A. miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer. PLoS One 2014, 9:e87039.
90. Heyn H., Engelmann M., Schreek S., Ahrens P., Lehmann U., Kreipe H., Schlegelberger B., Beger C. MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development. Int. J. Cancer 2011, 129:2797-2806.
91. Napolitano M., Comegna M., Succoio M., Leggiero E., Pastore L., Faraonio R., Cimino F., Passaro F. Comparative analysis of gene expression data reveals novel targets of senescence-associated microRNAs. PLoS One 2014, 9:e98669.
92. Arias-Romero L.E., Chernoff J. Targeting Cdc42 in cancer. Expert Opin. Ther. Targets 2013, 17:1263-1273.
93. Zhao Q., Rank G., Tan Y.T., Li H., Moritz R.L., Simpson R.J., Cerruti L., Curtis D.J., Patel D.J., Allis C.D., Cunningham J.M., Jane S.M. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat. Struct. Mol. Biol. 2009, 16:304-311.
94. Gu Z., Li Y., Lee P., Liu T., Wan C., Wang Z. Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells. PLoS One 2012, 7:e44033.
95. He Y., Dupree J., Wang J., Sandoval J., Li J., Liu H., Shi Y., Nave K.A., Casaccia-Bonnefil P. The transcription factor Yin Yang 1 is essential for oligodendrocyte progenitor differentiation. Neuron 2007, 55:217-230.
96. Cao R., Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr. Opin. Genet. Dev. 2004, 14:155-164.
97. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., Morey L., Van Eynde A., Bernard D., Vanderwinden J.-M., Bollen M., Esteller M., Di Croce L., de Launoit Y., Fuks F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871-874.
98. Chang C.J., Hung M.C. The role of EZH2 in tumour progression. Br. J. Cancer 2012, 106:243-247.
99. Yang Y., Yu J. EZH2, an epigenetic driver of prostate cancer. Protein Cell 2013, 4:331-341.
100. Chinaranagari S., Sharma P., Chaudhary J. EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer. Oncotarget 2014, 5:7172-7182.
101. Wang L.F., Huang S., Huang C., Li C.R., Li D.J. [Effect of 5-Aza-CdR on biological activity and inhibitor of DNA binding 4 gene expression in human erythroleukemia cell line K562], Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui. J. exp. hematol. Chin. Assoc. Pathophysiol. 2011, 19:1388-1392.
102. Qu F., Zhao C.H., Diao Y.Q., Zhu X.L., Chen J., Li M., Liu C.P., Jiang L., Jin J. [Methylation of Id4 gene and inhibitive effect of arsenic trioxide on it in Raji cells.]. Zhonghua Xue Ye Xue Za Zhi 2010, 31:821-825.
103. Beger C., Pierce L.N., Kruger M., Marcusson E.G., Robbins J.M., Welcsh P., Welch P.J., Welte K., King M.C., Barber J.R., Wong-Staal F. Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:130-135.
104. Carey J.P., Knowell A.E., Chinaranagari S., Chaudhary J. Id4 promotes senescence and sensitivity to doxorubicin-induced apoptosis in DU145 prostate cancer cells. Anticancer Res. 2013, 33:4271-4278.
105. Liggett W.H., Sidransky D. Role of the p16 tumor suppressor gene in cancer. J. Clin. Oncol. 1998, 16:1197-1206.
106. Muller P.A., Vousden K.H. p53 mutations in cancer. Nat. Cell Biol. 2013, 15:2-8.
107. Dell'Orso S., Ganci F., Strano S., Blandino G., Fontemaggi G. ID4: a new player in the cancer arena. Oncotarget 2010, 1:48-58.
108. Coradini D., Fornili M., Ambrogi F., Boracchi P., Biganzoli E. TP53 mutation, epithelial-mesenchymal transition, and stemlike features in breast cancer subtypes. J. Biomed. Biotechnol. 2012, 2012:254085.
109. Bookstein R., Rio P., Madreperla S.A., Hong F., Allred C., Grizzle W.E., Lee W.H. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:7762-7766.
110. Tamimi Y., Bringuier P.P., Smit F., van Bokhoven A., Debruyne F.M., Schalken J.A. p16 mutations/deletions are not frequent events in prostate cancer. Br. J. Cancer 1996, 74:120-122.
111. Network C.G.A. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.